These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553 [TBL] [Abstract][Full Text] [Related]
44. Differentiation between recurrent tumor and radiation necrosis in a child with anaplastic ependymoma after chemotherapy and radiation therapy. Beuthien-Baumann B; Hahn G; Winkler C; Heubner G Strahlenther Onkol; 2003 Dec; 179(12):819-22. PubMed ID: 14652670 [TBL] [Abstract][Full Text] [Related]
45. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Ogawa T; Kanno I; Shishido F; Inugami A; Higano S; Fujita H; Murakami M; Uemura K; Yasui N; Mineura K Acta Radiol; 1991 May; 32(3):197-202. PubMed ID: 2064862 [TBL] [Abstract][Full Text] [Related]
46. Role of (18) F-FDOPA PET/CT imaging in endocrinology. Santhanam P; Taïeb D Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984 [TBL] [Abstract][Full Text] [Related]
47. Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Okamoto S; Shiga T; Hattori N; Kubo N; Takei T; Katoh N; Sawamura Y; Nishijima K; Kuge Y; Tamaki N Ann Nucl Med; 2011 Apr; 25(3):213-20. PubMed ID: 21188660 [TBL] [Abstract][Full Text] [Related]
48. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. Walter F; Cloughesy T; Walter MA; Lai A; Nghiemphu P; Wagle N; Fueger B; Satyamurthy N; Phelps ME; Czernin J J Nucl Med; 2012 Mar; 53(3):393-8. PubMed ID: 22323780 [TBL] [Abstract][Full Text] [Related]
49. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Galldiks N; Langen KJ; Pope WB Neuro Oncol; 2015 Nov; 17(11):1434-44. PubMed ID: 26130743 [TBL] [Abstract][Full Text] [Related]
50. High 18F-FDOPA PET Uptake in Primary Central Nervous System Lymphoma. Salgues B; Kaphan E; Molines E; Brun G; Guedj E Clin Nucl Med; 2021 Jan; 46(1):e59-e60. PubMed ID: 32956128 [TBL] [Abstract][Full Text] [Related]
51. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339 [TBL] [Abstract][Full Text] [Related]
52. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor. Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535 [TBL] [Abstract][Full Text] [Related]
53. 3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Seibyl JP; Chen W; Silverman DH Semin Nucl Med; 2007 Nov; 37(6):440-50. PubMed ID: 17920351 [TBL] [Abstract][Full Text] [Related]
54. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Patronas NJ; Di Chiro G; Brooks RA; DeLaPaz RL; Kornblith PL; Smith BH; Rizzoli HV; Kessler RM; Manning RG; Channing M; Wolf AP; O'Connor CM Radiology; 1982 Sep; 144(4):885-9. PubMed ID: 6981123 [TBL] [Abstract][Full Text] [Related]
55. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911 [TBL] [Abstract][Full Text] [Related]
56. [18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression. Dadone-Montaudié B; Ambrosetti D; Dufour M; Darcourt J; Almairac F; Coyne J; Virolle T; Humbert O; Burel-Vandenbos F PLoS One; 2017; 12(9):e0184625. PubMed ID: 28937983 [TBL] [Abstract][Full Text] [Related]
57. Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera--a pilot study. Stokkel M; Stevens H; Taphoorn M; Van Rijk P Nucl Med Commun; 1999 May; 20(5):411-7. PubMed ID: 10404525 [TBL] [Abstract][Full Text] [Related]
58. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148 [TBL] [Abstract][Full Text] [Related]
59. Semiquantitative analysis using thallium-201 SPECT for differential diagnosis between tumor recurrence and radiation necrosis after gamma knife surgery for malignant brain tumors. Matsunaga S; Shuto T; Takase H; Ohtake M; Tomura N; Tanaka T; Sonoda M Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):47-52. PubMed ID: 22541963 [TBL] [Abstract][Full Text] [Related]
60. GMP production of [18F]FDOPA and issues concerning its quality analyses as in USP "Fluorodopa F 18 Injection". Kao CH; Hsu WL; Xie HL; Lin MC; Lan WC; Chao HY Ann Nucl Med; 2011 Jun; 25(5):309-16. PubMed ID: 21344169 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]